207 related articles for article (PubMed ID: 34718928)
1. Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.
Milovanova LY; Taranova MV; Milovanova SY; Kozlovskaya Lysenko LV; Pasechnik AI; Kozlov VV; Beketov VD; Volkov AV; Ratanov M
Int Urol Nephrol; 2022 Jul; 54(7):1613-1621. PubMed ID: 34718928
[TBL] [Abstract][Full Text] [Related]
2. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
Milovanova LY; Dobrosmyslov IA; Milovanov YS; Taranova MV; Kozlov VV; Milovanova SY; Kozevnikova EI
Ter Arkh; 2018 Jun; 90(6):48-54. PubMed ID: 30701904
[TBL] [Abstract][Full Text] [Related]
4. [Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in patients with chronic kidney disease].
Taranova MV; Milovanova LY; Kozlovskaya Lysenko LV; Milovanova SY; Androsova TV; Zubacheva DO; Lebedeva MV; Dobrosmyslov IA; Kozlov VV; Kuchieva AM; Li OA; Reshetnikov VA
Ter Arkh; 2019 Jun; 91(6):85-92. PubMed ID: 36471601
[TBL] [Abstract][Full Text] [Related]
5. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
6. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
[TBL] [Abstract][Full Text] [Related]
7. FGFR4 and Klotho Polymorphisms Are Not Associated with Cardiovascular Outcomes in Chronic Kidney Disease.
Sellier AB; Seiler-Mußler S; Emrich IE; Böhm M; Fliser D; Zawada AM; Heine GH
Am J Nephrol; 2021; 52(10-11):808-816. PubMed ID: 34673637
[TBL] [Abstract][Full Text] [Related]
8. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
Silva AP; Mendes F; Carias E; Gonçalves RB; Fragoso A; Dias C; Tavares N; Café HM; Santos N; Rato F; Leão Neves P; Almeida E
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934737
[TBL] [Abstract][Full Text] [Related]
9. Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.
Yang K; Wang C; Nie L; Zhao X; Gu J; Guan X; Wang S; Xiao T; Xu X; He T; Xia X; Wang J; Zhao J
J Am Soc Nephrol; 2015 Oct; 26(10):2434-46. PubMed ID: 25804281
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.
Smith K; deFilippi C; Isakova T; Gutiérrez OM; Laliberte K; Seliger S; Kelley W; Duh SH; Hise M; Christenson R; Wolf M; Januzzi J
Am J Kidney Dis; 2013 Jan; 61(1):67-73. PubMed ID: 22883134
[TBL] [Abstract][Full Text] [Related]
11. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of fibroblast growth Factor-23 as a correlate of cardiovascular disease among individuals with chronic kidney disease, hypertensives, and healthy controls.
Abiola BI; Raji YR; Ajayi S; Adeoye AM; Salako BL; Arije A; Kadiri S
Niger J Clin Pract; 2022 Aug; 25(8):1247-1255. PubMed ID: 35975371
[TBL] [Abstract][Full Text] [Related]
13. Alpha Klotho and Fibroblast Growth Factor-23 Among Alcoholics.
Quintero-Platt G; González-Reimers E; Rodríguez-Gaspar M; Martín-González C; Pérez-Hernández O; Romero-Acevedo L; Espelosín-Ortega E; Vega-Prieto MJ; Santolaria-Fernández F
Alcohol Alcohol; 2017 Sep; 52(5):542-549. PubMed ID: 28651327
[TBL] [Abstract][Full Text] [Related]
14. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
15. [Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2-5D].
Milovanova LY; Lysenko Kozlovskaya LV; Milovanova SY; Taranova MV; Kozlov VV; Reshetnikov VA; Lebedeva MV; Androsova TV; Zubacheva DO; Chebotareva NV
Ter Arkh; 2020 Jul; 92(6):37-45. PubMed ID: 33346491
[TBL] [Abstract][Full Text] [Related]
16. Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.
Milovanova L; Fomin V; Moiseev S; Taranova M; Milovanov Y; Lysenko Kozlovskaya L; Kozlov V; Kozevnikova E; Milovanova S; Lebedeva M; Reshetnikov V
Clin Exp Nephrol; 2018 Dec; 22(6):1351-1359. PubMed ID: 29948444
[TBL] [Abstract][Full Text] [Related]
17. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
[TBL] [Abstract][Full Text] [Related]
18. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
Kim HJ; Kang E; Oh YK; Kim YH; Han SH; Yoo TH; Chae DW; Lee J; Ahn C; Oh KH
BMC Nephrol; 2018 Mar; 19(1):51. PubMed ID: 29506503
[TBL] [Abstract][Full Text] [Related]
19. [Low protein diet with essential amino acids ketoanalogues combination can affect serum FGF-23 and Klotho levels in chronic kidney disease 3b-4 stages patients: randomized pilot study].
Milovanova LY; Kozlovskaya Lysenko LV; Androsova TV; Lebedeva MV; Taranova MV; Milovanova SY; Kondratyeva TB; Zubacheva DO; Tchebotareva NV; Kozlov VV; Kuchieva AM; Li OA; Reshetnikov VA
Ter Arkh; 2019 Jun; 91(6):47-56. PubMed ID: 36471595
[TBL] [Abstract][Full Text] [Related]
20. FGF23 induces left ventricular hypertrophy.
Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
